Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild type colorectal cancer （OGSG 1602）
国際学会発表
Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory tofluoropyrimidine-and platinum-based chemotherapy (OGSG1201)
Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus platinum (OGSG0701)
Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus CDDP（OGSG0701）
A Phase I/II Trial of Radiotherapy Concurrent with TS-1 Plus Cisplatin in Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group（OGSG1205）
A phase ll study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer ; OGSG1101, HGCSG1102, T-CORE1101 Intergroup study (HERBIS-1 trial)
A phase ll study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer ; OGSG1101, HGCSG1102, T-CORE1101 Intergroup study (HERBIS-1 trial)
A phase ll study of new combination regimen with trastuzumab, S-1 and CDDP in HER2- positive advanced gastric cancer; OGSG1101, HGCSG1102, T-CORE1101 Intergroup study (HERBIS-1 trial)
A phase ll study of Trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer; OGSG1101, HGCSG1102, T-CORE1101 Intergroup study(HERBIS-1 trial)
Multicenter phase II study of triplet combination chemotherapy with paclitaxel, cisplatin, and S-1 for advanced gastric cancer (OGSG0703)